Low dose cyclophosphamide: Mechanisms of T cell modulation

Mutsa Tatenda Madondo, Michael Quinn, Magdalena Plebanski

Research output: Contribution to journalReview ArticleResearchpeer-review

112 Citations (Scopus)


Cyclophosphamide is considered one of the most successful chemotherapy drugs and is listed on the World Health Organisations List of Essential Medicines. Since its initial synthesis in 1958, it has been widely used to treat a range of cancers but its use has been declining due to the advent of platinum based and other chemotherapy agents. However, cyclophosphamide is still used either as a single agent or as adjuvant therapy to treat lymphomas, and breast and ovarian cancers at much lower doses. The efficacy of low dose cyclophosphamide is primarily due to its ability to promote anti-tumour immunity, by selectively depleting regulatory T cells and enhancing effector T cell function. Compared to effecter T cells, regulatory T cells have metabolic adaptations that make them more susceptible to cyclophosphamide-mediated cytotoxicity. In this review, we highlight the potential for improving the efficacy of low dose cyclophosphamide by combining insights on the mechanisms of cyclophosphamide-mediated cytotoxicity, and how these cytotoxic effects of cyclophosphamide influence T cell function, thereby contributing to anti-tumour immunity.

Original languageEnglish
Pages (from-to)3-9
Number of pages7
JournalCancer Treatment Reviews
Publication statusPublished - 1 Jan 2016


  • Acrolein
  • Chemotherapy
  • Cyclophosphamide
  • GSH
  • T cells

Cite this